Sunesis pharmaceuticals inc. (SNSS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue:
License and other revenue

120

-

-

-

-

0

0

0

237

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

14

License and other revenue

-

-

-

-

-

-

-

-

-

-

-

0

669

676

610

610

640

670

683

854

854

896

854

1,989

1,995

1,989

1,989

1,989

1,989

-

265

1,500

-

0

1,000

0

4,000

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

0

669

676

610

610

640

670

683

854

854

896

854

1,989

1,995

1,989

1,989

1,989

1,989

-

265

1,500

-

0

1,000

0

4,000

0

14

Operating expenses:
Research and development

3,690

4,947

3,534

3,683

3,248

3,301

3,587

3,758

3,969

3,674

6,763

4,941

6,162

4,815

5,251

6,606

6,209

7,628

5,259

6,302

4,512

5,968

6,939

7,206

7,552

6,883

6,957

7,674

7,377

7,589

6,878

8,072

6,646

6,326

6,217

5,950

4,070

3,479

2,970

General and administrative

2,228

2,480

2,507

2,523

2,439

2,459

2,690

2,824

3,359

2,760

3,175

3,671

3,942

3,934

3,889

3,997

4,295

4,382

3,994

5,175

5,111

6,082

7,226

6,387

3,417

2,698

2,807

2,889

2,444

2,473

2,331

2,182

2,189

2,159

2,155

1,975

2,014

1,804

1,862

Total operating expenses

5,918

7,427

6,041

6,206

5,687

5,760

6,277

6,582

7,328

6,434

9,938

8,612

10,104

8,749

9,140

10,603

10,504

12,010

9,253

11,477

9,623

12,050

14,165

13,593

10,969

9,581

9,764

10,563

9,821

10,062

9,209

10,254

8,835

8,485

8,372

7,925

6,084

5,283

4,832

Loss from operations

-5,798

-5,354

-6,041

-6,206

-5,687

-5,760

-6,277

-6,582

-7,091

-6,434

-9,938

-8,612

-9,435

-8,073

-8,530

-9,993

-9,864

-11,340

-8,570

-10,623

-8,769

-11,154

-13,311

-11,604

-8,974

-7,592

-7,775

-8,574

-7,832

-8,073

-8,944

-8,754

-8,835

-8,485

-7,372

-7,925

-2,084

-5,283

-4,818

Interest expense

70

71

71

111

261

295

291

287

281

280

288

344

484

474

473

476

298

234

233

233

239

311

391

470

547

623

695

768

831

839

385

316

315

-

-

0

0

-

-

Other income, net

93

138

170

76

88

58

63

29

99

91

67

114

85

10

49

23

76

-4

1,782

1,907

-120

10,142

-1,623

293

-5,052

1,038

863

1,152

-2,961

4,860

-8,067

491

-4,774

4

2,358

-302

3,924

199

34

Net loss

-5,775

-5,287

-5,942

-6,241

-5,860

-5,997

-6,505

-6,840

-7,273

-6,623

-10,159

-8,842

-9,834

-8,537

-8,954

-10,446

-10,086

-11,578

-7,021

-8,949

-9,128

-1,323

-15,325

-11,781

-14,573

-7,177

-7,607

-8,190

-11,624

-4,052

-17,396

-8,579

-13,924

-8,740

-5,014

-8,227

1,840

-5,084

-4,784

Unrealized loss on available-for-sale securities

-1

-

-

-

-

0

1

4

2

-

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

9

4

-17

-6

-1

13

-9

3

0

2

2

-2

-11

7

-12

9

-17

-21

41

2

-13

-11

-1

2

21

12

-

-

Comprehensive loss

-5,776

-5,286

-5,942

-6,241

-5,860

-5,997

-6,504

-6,836

-7,271

-6,629

-10,151

-8,833

-9,830

-8,554

-8,960

-10,447

-10,073

-11,587

-7,018

-8,949

-9,126

-1,321

-15,327

-11,792

-14,566

-7,189

-7,598

-8,207

-11,645

-4,011

-17,394

-8,592

-13,935

-8,741

-5,012

-8,206

1,852

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,949

-

-

-

-11,781

-

-

-7,607

-8,190

-

-

-17,396

-8,579

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,816

-

-

-

-12,114

-

-

-8,329

-9,336

-

-

-17,396

-9,332

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,513

-

-

-

60,246

-

-

51,698

51,630

-

-

47,398

46,953

-

-

-

46,295

45,894

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,525

-

-

-

61,895

-

-

53,271

53,268

-

-

47,398

47,286

-

-

-

46,295

47,866

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.12

-

-

-

-0.20

-

-

-0.15

-0.16

-

-

-0.37

-0.18

-

-

-

-0.18

0.04

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.15

-

-

-

-0.20

-

-

-0.16

-0.18

-

-

-0.37

-0.20

-

-

-

-0.18

0.04

-

-

Basic and diluted loss per common share:
Net loss

-5,775

-5,287

-5,942

-6,241

-5,860

-5,997

-6,505

-6,840

-7,273

-6,623

-10,159

-8,842

-9,834

-8,537

-8,954

-10,446

-10,086

-11,578

-7,021

-8,949

-9,128

-

-15,325

-11,781

-14,573

-7,177

-7,607

-8,190

-11,624

-4,052

-17,396

-8,579

-13,924

-8,740

-5,014

-8,227

1,840

-5,084

-4,784

Shares used in computing net loss per common share

111,393

112,114

105,070

72,190

59,142

37,471

36,095

34,417

34,345

31,836

23,678

21,521

21,029

-

14,503

14,493

14,443

-

12,463

-

67,641

-

60,549

-

56,313

-

-

-

51,587

-

-

-

46,793

-

46,714

-

-

-

-

Net loss per common share

-0.05

-0.02

-0.06

-0.09

-0.10

-0.16

-0.18

-0.20

-0.21

-0.14

-0.43

-0.41

-0.47

-

-0.62

-0.72

-0.70

-

-0.56

-

-0.13

-

-0.25

-

-0.26

-

-

-

-0.23

-

-

-

-0.30

-

-0.11

-

-

-

-

Basic and diluted loss attributable to common stockholders per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.14

-0.44

Shares used in computing basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36,970

10,912